Type 2 diabetes mellitus (T2DM) and HCV (hepatitis C virus) infection are the important public health problem. There is marked geographic variation exists for HCV infection rates ranging from 1.3%–1.6% in the United States to 15% in Egypt(1). The population prevalence of HCV infection is 1% and of T2DM is 8.3% in India(2). HCV–related cirrhosis is the leading indication for liver transplantation in the western world.(3)  Chronic hepatitis C virus infection mainly affects liver but can be associated with various extrahepatic manifestations including arthritis, vasculitis, sicca syndrome, porphyria cutanea tarda, lichen planus, nephropathies, lung fibrosis and B–cell lymphoproliferative diseases.(4) Chronic hepatitis C (CHC) is further associated with endocrinal disorder namely T2DM, metabolic syndrome, and atherosclerosis.(5) A large number of studies report an increased risk of T2DM in patients with chronic hepatitis C virus infection(6)(7). HCV and its association with T2DM were first confirmed in HCV–related cirrhosis by Allison et al(8). Subsequent studies had confirmed that such association was present in every stage of HCV infection.(9,10) whereas few studies could not confirm this association in the absence of liver dysfunction(6). Association of CHC and T2DM  holds true even when comparing patients with HCV related liver disease compared to that of HBV related liver disease(11,12).